Saturday 17 October 2026
Export SLGL’s income statement to Excel — free account
Sol-Gel Technologies Ltd.
SLGL Healthcare Biotechnology
Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS fell 127.1% and free cash flow fell 8.76%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
64.25
4.45
−6.48%
Follow SLGL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.28 | 6.06 | 12.17 | 135.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
135.58 | 364.60 | 697.97 | (29.34) | |
P/B ratio |
3.12 | 5.15 | 4.37 | 5.04 | |
Price to Tangible BV |
3.12 | 5.15 | 4.37 | 5.04 | |
EV/Sales |
6.63 | 8.19 | 12.85 | 144.80 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.30) | (7.71) | (11.52) | (12.24) | |
EV/FCF |
(4.29) | (7.70) | (11.51) | (12.22) | |
Quick Ratio |
4.99 | 4.21 | 8.54 | 9.87 | |
Current Ratio |
5.15 | 4.37 | 8.84 | 10.37 | |
Net Debt/EBITDA |
3.31 | 7.04 | 13.70 | 11.52 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.49 | 0.59 | 0.43 | 0.04 | |
Operating CF/Net income |
0.00 | (0.11) | 0.00 | 2.25 | |
Capex/Depreciation |
— | 0.06 | — | (0.67) | |
Research and Development Expense of Revenue |
1,432.75% | 514.94% | 2,579.63% | 629.27% | |
Selling, General and Administrative Expense of Revenue |
239.25% | 82.90% | 1,089.81% | 174.96% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.28 | 0.17 | 0.22 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.18%) | (5.29%) | (0.43%) | (7.61%) | |
Free Cash Flow Yield |
(36.06%) | (17.55%) | (9.17%) | (8.77%) | |
Revenue per Share |
0.14 | 0.25 | 0.04 | 0.18 | |
Operating CF per Share |
0.00 | 0.12 | 0.00 | (2.53) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.00 | 0.12 | 0.00 | (2.53) | |
Cash per Share |
7.48 | 8.61 | 18.62 | 14.65 | |
Shareholders Equity per Share |
9.34 | 8.19 | 18.12 | 14.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.34 | 8.19 | 18.12 | 14.70 | |
Free Cash Flow |
— | 0.33 | — | (8.29) | |
Working Capital |
25.51 | 20.80 | 49.48 | 46.15 | |
Capital Expenditures |
— | 0.01 | — | (0.03) | |
Net Current Asset Value |
23.09 | 19.87 | 48.65 | 45.42 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (0.01) | 0.00 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.43 | 2.78 | 2.48 | 5.38 | |
Average Payables |
1.17 | 1.00 | 0.61 | 1.04 | |
Average Assets |
38.79 | 32.88 | 42.81 | 46.53 | |
Average Common Equity |
30.37 | 25.83 | 35.79 | 39.99 |
Columns are period end dates